COMMUNIQUÉS West-GlobeNewswire

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey
06/03/2025
Lenox Hill Radiology (LHR) in New York and New Jersey Imaging Network (NJIN) to add Nociscan across multiple sites BROOMFIELD, Colo., March 06, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) ( [...]
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI)
06/03/2025
SARASOTA, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced the [...]
Advanced Biomed Inc. Announces Pricing of Initial Public Offering
06/03/2025
Tainan, Taiwan, March 06, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (the “Company” or “Advanced Biomed”), a biotechnology company focused on early screening and detection, diagnosis and staging, and treatment of [...]
Autonomix Medical, Inc. Announces Abstract Highlighting Technology and Early Proof-of-Concept Study Results Accepted at the Society of Interventional Radiology (SIR) Annual Scientific Meeting
06/03/2025
THE WOODLANDS, TX, March 06, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how [...]
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
05/03/2025
WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the [...]
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions
05/03/2025
McKemey joins Certara to accelerate growth of its strategic drug development solutions RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, [...]
ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
05/03/2025
neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company [...]
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025
05/03/2025
LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2024 financial results on [...]
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
05/03/2025
First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a bispecific 2 + 1 T cell engager (TCE) targeting mesothelin Acceleration of [...]
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
05/03/2025
On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025 Company to present further in vivo HSC preclinical data and further in vivo preclinical [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05/03/2025
NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX ), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, [...]
Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual
05/03/2025
ROCKVILLE, Md., March 05, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high [...]
Enovis to Participate in Upcoming Investor Conferences
05/03/2025
Wilmington, DE, March 05, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following [...]
Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance
05/03/2025
MENLO PARK, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, [...]
Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults
05/03/2025
Robust, antigen-specific responses in the nasal cavity following oral administration underscore the efficiency of Vaxart’s oral vaccine platform in generating mucosal antibody responses beyond the site of administration [...]
Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea
05/03/2025
DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) achieved the co-primary and all secondary endpoints with no significant safety issues when [...]
WORK Medical Technology Group LTD Announces Implementation of Dual-Class Share Structure Effective March 6, 2025
05/03/2025
Hangzhou, China, March 05, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices, through its subsidiary, Work (Hangzhou) Medical [...]
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
05/03/2025
Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE Completed Type D Meeting with FDA to Enable FT819 Off-the-Shelf CAR T- [...]
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
05/03/2025
Initiated Anaphylm™ (epinephrine) Sublingual Film NDA filing process with FDA Anaphylm pre-commercial activities underway; launch expected in Q1 2026, if approved by the FDA Initial Anaphylm pediatric clinical trial [...]

Pages